Clinical trials: Stenoses, Aortic
Williams Syndrome, Supravalvular Aortic Stenosis
Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank
Williams syndrome is a rare genetic disorder occurring in 1:8000-12,000 individuals. It is caused by the deletion of 25-27 coding genes, including elastin (ELN) on the 7th human chromosome.
- Conditions
- Williams Syndrome, Supravalvular Aortic Stenosis, Cardiovascular Disease
- Trial name
- NCT02706639
- Where
- 3 sites in United States
- Volunteers
- 305 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Severe Aortic Stenosis
Effect of Double-Tap Optimization on Valve Expansion and Hemodynamics in Balloon-expandable Transcatheter Aortic Valve Implantation: A Randomized Clinical Trial (DO-OPT TAVI Trial)
This study will compare two balloon inflation strategies during transcatheter aortic valve implantation (TAVI), a procedure used to replace a severely narrowed aortic valve through a catheter.
- Trial name
- NCT07912905
- Testing
- Double-Tap Balloon Post-dilatation, Conventional Single-Inflation TAVI
- Volunteers
- 250 people
- Sponsor
- Yonsei University
Moderate Aortic Valve Stenosis
The Role of SGLT2i in Management of Moderate AS
Background: The aortic valve is like a door in the heart that lets blood flow out to the body. Over time, this valve can get worn out and become too narrow, leading to a condition called aortic stenosis.
- Trial name
- NCT06469645
- Testing
- Empagliflozin 10 MG
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- University of East Anglia
Aortic Stenosis
ACURATE Neo™ TA Delivery System in Patient With Severe Aortic Stenosis
The purpose of this investigation is to collect data pertaining to the safety and performance of the ACURATE neo (TM) Aortic Bioprosthesis as implanted with the ACURATE neo (TM) TA Transapical Delivery System.
- Trial name
- NCT02950428
- Testing
- ACURATE neo™TA Delivery System
- Where
- 7 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Symetis SA
Aortic Stenosis, Myocardial Fibrosis
Mechanism of Decompensation Evaluation - Aortic Stenosis
Aortic stenosis is the most common heart valve disease requiring intervention in high income countries. It is characterised by progressive valvular thickening, and restriction as well is hypertrophy and fibrosis of the left…
- Conditions
- Aortic Stenosis, Myocardial Fibrosis, Left Ventricular Hypertrophy
- Trial name
- MODE-AS (NCT03332745)
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- University of Edinburgh
Aortic Stenosis
AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
ACASA-TAVI is a pragmatic randomized controlled trial assessing the value of anticoagulation therapy versus the standard antiplatelet therapy after transcatheter aortic valve implantation in patients with aortic stenosis.
- Trial name
- ACASA-TAVI (NCT05035277)
- Testing
- Acetylsalicylic acid, Apixaban, Rivaroxaban
- Where
- 3 sites in Norway
- Volunteers
- 360 people
- Sponsor
- Oslo University Hospital
Aortic Stenosis
PERIGON Pivotal Trial
To evaluate the safety and effectiveness of the Model 400 aortic valve bioprosthesis.
- Trial name
- PERIGON (NCT02088554)
- Testing
- Model 400 aortic valve bioprosthesis
- Where
- 38 sites in United States, Canada and 6 more
- Volunteers
- 1,312 people
- Sponsor
- Medtronic Cardiac Surgery
Severe Aortic Valve Stenosis, Aortic Valve Stenosis
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
The optimal pharmacological therapy after transcatheter aortic valve implantation (TAVI) to prevent valve thrombosis and reduce thromboembolic complications without significantly increasing the risk of bleeding is not yet fully…
- Conditions
- Severe Aortic Valve Stenosis, Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Aortic Valve Implantation (TAVI)
- Trial name
- REAC-TAVI2 (NCT05283356)
- Testing
- Ticagrelor 60mg
- Where
- Spain
- Volunteers
- 1,206 people
- Sponsor
- Fundacin Biomedica Galicia Sur
Aortic Valve Stenosis
Non-Contrast Magnetic Resonance Angiography Assessment of Patients Referred for Transcatheter Aortic Valve Implantation
The overall objective of this proposal is to examine the feasibility and accuracy of non-contrast magnetic resonance angiography (MRA) to comprehensively evaluate individuals referred for transcatheter aortic valve implantation…
- Trial name
- NCT02007967
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Michigan
Trans Catheter Aortic Valve, Aortic Stenosis
Functional and Quality of Life Improvement Following Transcatheter Heart Valve Implantation
The objective is to observe trends in patient characteristics and outcomes after aortic or mitral transcatheter heart valve replacement over time.
- Trial name
- NCT02023060
- Where
- 5 sites in Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Severe Aortic Stenosis
Transfemoral TAVI With or Without Coronary Angiogram in Patients With Severe Aortic Stenosis (PURE TAVI)
This study will be conducted in patients with severe aortic stenosis who are referred for transcatheter aortic valve implantation (TAVI). TAVI is the recommended treatment for severe aortic stenosis.
- Trial name
- PURETAVI (NCT06898086)
- Testing
- Transcatheter aortic valve implantation
- Where
- 23 sites in Austria, Czechia and 5 more
- Volunteers
- 620 people
- Sponsor
- Rede Optimus Hospitalar SA
Hypertrophic Cardiomyopathy
3D Non-invasive Myocardial Electrical Propagation Mapping as a New Tool to Predict Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is very common. The thickened heart muscle can disrupt the normal functioning of the heart's electrical system, resulting in fast or irregular heartbeats.
- Trial name
- 3D-CMH (NCT03550573)
- Testing
- CardioInsight™ Noninvasive 3D Mapping System
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Aortic Valve Stenosis, Aortic Valve Insufficiency
Avalus European Registry - an Observational Study to Evaluate Safety and Efficacy in a Real World Population
This is a prospective, observational, single-arm, multi-center registry of patients undergoing bioprosthetic aortic valve replacement with the Avalus valve.
- Trial name
- Avalus (NCT05572710)
- Where
- 19 sites in Belgium, Denmark and 6 more
- Volunteers
- 1,000 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Hypertrophic Cardiomyopathy
Study of Hypertrophic Cardiomyopathy Under Stress Conditions. Concordance Between Two Complementary Tests: Stress MRI and Exercice Stress Echocardiography
Hypertrophic cardiomyopathy (HCM) is a primitive myocardic disease and the first of genetic cardiac diseases. The definition of HCM is an increase of the myocardial thickness of the left ventricle (LV) wall without any other…
- Trial name
- CMHStress (NCT02500420)
- Testing
- Diagnosis examens
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Montpellier
Moderate Aortic Valve Stenosis
Aortic Valve Replacement for Moderate Aortic Stenosis With Left Ventricular Decompensation Early Feasibility Study
Obtain safety and effectiveness data to support expansion for aortic valve replacement to include patients with moderate aortic stenosis and left ventricular decompensation.
- Trial name
- NCT07060183
- Testing
- Ross procedure
- Sponsor
- Dermed Diagnostics, Inc.
Aortic Valve Stenosis
Impact of Local Tissue Inflammation on Intramyocardial Conduction Pathways Post Percutaneous Valve : Evaluation by Positron Emission Tomography on Exploratory Cohort
Aortic valve stenosis is the most common valve disease leading to surgical or percutaneous intervention in Europe and North America.
- Trial name
- IMPACT (NCT05308888)
- Testing
- 18F-FDG PET-CT
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Brest
Aortic Stenosis Disease
Clinical and CPET Parameters That Predict Improvement in Functional Capacity After TAVI
Determining Clinical and Cardiopulmonary exercise testing Parameters that may predict Improvement in Capacity After Transcatheter Aortic Valve Implantation
- Trial name
- NCT06833762
- Where
- Spain
- Volunteers
- 161 people
- Sponsor
- Hospital Clinic of Barcelona
Aortic Valve Stenosis, Aortic Valve Failure
Portico Valve-in-Valve Retrospective Registry
The objective of this data-collection study is to retrospectively evaluate the safety and clinical performance of the Portico transthoracic aortic valve for Valve-in-Valve treatment of a failed aortic surgical bioprosthetic valve…
- Conditions
- Aortic Valve Stenosis, Aortic Valve Failure, Aortic Insufficiency, Aortic Stenosis
- Trial name
- NCT05002088
- Testing
- Transcatheter Aortic Valve Replacement
- Where
- 7 sites in Australia, Denmark and 2 more
- Volunteers
- 71 people
- Sponsor
- Abbott Medical Devices
Ischemic Cardiomyopathy, Dilated Cardiomyopathy
Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium
Scanning the heart using magnetic resonance imaging (MRI) enables detailed assessment of its structure and function. MRI can give more detailed information about the heart by using a contrast 'dye' that is injected into a vein…
- Conditions
- Ischemic Cardiomyopathy, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy
- Trial name
- NCT03607669
- Testing
- Mangafodipir trisodium
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Aortic Stenosis, TAVI(Transcatheter Aortic Valve Implantation)
Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial
Aspirin group: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.
- Conditions
- Aortic Stenosis, TAVI(Transcatheter Aortic Valve Implantation), Aspirin, DAPT(Dual Antiplatelet Therapy)
- Trial name
- NCT06007222
- Testing
- Aspirin group, Non-antithrombotic group
- Where
- Japan
- Volunteers
- 400 people
- Sponsor
- OCEAN-SHD Study Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.